Features | Partner Sites | Information | LinkXpress
Sign In
AB Sciex
Bio-Rad Diabetes Division
FOCUS DIAGNOSTICS, INC.

Biomarkers Help Predict Outcome in Deadly Lung Disease

By Labmedica International staff writers
Posted on 15 Oct 2013
Image: Histopathology of idiopathic pulmonary fibrosis (Photo courtesy of the American Thoracic Society).
Image: Histopathology of idiopathic pulmonary fibrosis (Photo courtesy of the American Thoracic Society).
A gene expression profile has been identified that can predict outcomes and lead to better treatment for one of the most lethal lung diseases, idiopathic pulmonary fibrosis (IPF).

In most cases of IPF the cause cannot be identified, and there is no cure other than a lung transplant and while some patients experience a progressive course that leads to death within one to two years, others experience a relative stable disease.

Scientists from Yale University (New Haven, CT, USA) with colleagues from other institutions recruited a discovery cohort of 45 patients from the University of Chicago (IL, USA) and 75 patients in a replication cohort from the University of Pittsburgh (PA, USA). The goal of the study was to identify changes in expression of genes in the blood that are predictive of poor outcomes among patients with IPF.

The teams analyzed the expression of the genes in the whole genome of patients with IPF, using peripheral blood mononuclear cell (PBMC). They identified 52 genes that significantly correlated with outcome. They further found that the decreased expression of four genes that encode for cluster of differentiation 28 (CD28), inducible T-cell co-stimulator (ICOS), lymphocyte-specific protein tyrosine kinase (LCK), and interleukin 2 (IL2)-inducible T-cell kinase (ITK). These genes predicted shorter survival time in patients with IPF.

The investigators believe the discovery of these biomarkers will help physicians better predict disease presence, severity, and prognosis in IPF patients. Naftali Kaminski, MD, a professor at Yale School of Medicine and a senior author of the study said, “Given the fact that lung transplantation is the only therapy that has shown to improve survival in IPF, our test could allow physicians to refer IPF patients for lung transplant at the right time, not too late and not too early.”

The author concluded that microarray-derived 52-gene expression profile or quantitative reverse transcription polymerase chain reaction (qRT-PCR) of CD28, ICOS, LCK, and ITK members of this signature was sufficient to identify IPF patients destined for poor outcomes. Combining gene expression data with clinical parameters enhanced outcome prediction; thus, the results could have considerable value in clinical evaluations and management of patients with this devastating lung disease. The study was published on October 2, 2013, in the journal Science Translational Medicine.

Related Links:
Yale University
University of Chicago
University of Pittsburgh



PURITAN MEDICAL
DiagCor Bioscience
77 ELEKTRONIKA
comments powered by Disqus
Life Technologies

Channels

Clinical Chemistry

view channel
Image:  The Agilent 6890 GC with 5973 Mass Spectrometer and Tekmar Velocity XPT Purge & Trap (Photo courtesy of Gen Tech).

Low Levels of Prohormone Predicts Coronary Heart Disease

The adrenal sex hormone dehydroepiandrosterone (DHEA), which is present in serum mainly as the sulfate DHEA-S, is the most abundant steroid hormone in human blood and its levels decline dramatically with age.... Read more

Microbiology

view channel
Image: The causative parasite of Chagas disease Trypanosoma cruzi in a blood film (Photo courtesy of the CDC - US Centers for Disease Control and Prevention).

Undiagnosed Chagas Disease Emerging as Public Health Threat

Chagas disease or American trypanosomiasis is typically spread to people through the feces of blood-sucking triatomine bugs sometimes called kissing bugs because they feed on people's faces during the night.... Read more

Pathology

view channel

Identification of Independent Primary Lung Tumors and Tumors with Metastases Using Next-Generation DNA Sequencing

A team of oncologists and surgeons used a next-generation DNA sequencing (NGS) technique to determine whether non-small-cell lung cancer patients with multiple tumors carried independent primary tumors or a single primary tumor that had metastasized. For patients with multiple tumors, distinguishing independent primary... Read more

Industry News

view channel

Oncology Companion Diagnostics Sector Grows to Over USD 1 Billion

The market for diagnostic test and pharmaceutical drug pairs for cancer treatment has grown significantly, according to the report “Companion Diagnostic Markets” from healthcare market research firm Kalorama Information (New York City, NY, USA). The global companion diagnostics (CDx) market is valued at about USD 1.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.